AVDL (Avadel Corp) Wutah bathi resik saben saham ing taun iki

Simbol resmi perusahaan avadel.com (AVDL)

Avadel Pharmaceuticals (AVDL) relies on the US domestic market, facing only indirect influence from Asian supplies. Patent disputes and the recognition of narcolepsy therapy create pressure, as visualized by the annual EPS percentage change; the 125.60 metric determines this level. Commercial demand for the orphan drug will drive growth, provided management effectively optimizes distribution costs.

AVDL (Avadel Pharmaceuticals) riwayat Wutah bathi saben saham ing taun lumaku saka 04.07.2022 nganti 28.02.2026

Rincian metrik komprehensif lan analitis Avadel Pharmaceuticals plc (AVDL)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:Avadel Pharmaceuticals
Produk asil prodhuksi avadel.com

Avadel Pharmaceuticals (AVDL) revenues are critically dependent on the commercialization of its narcolepsy drug and insurance reimbursement terms. The dynamics of these factors are reflected in the annual EPS growth rate, which measures the percentage change in net income per share, revealing the impact of operating expenses and debt load on final profitability, thereby allowing investors to promptly recognize risks of capital degradation.